Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BCYC
BICYCLE THERAPEUTICS PLC
NASDAQ
$4.29
▲ UP 1.30% (0.06)

KEY STATISTICS

Market Cap$294.58 M
52w High$9.16
52w Low$3.75
Dividend Yield—
Frequency—
P/E-1.57
Volume76.90K
Shares Out.69.39M

COMPANY

LEADERSHIP

Kevin Lee
CHIEF EXECUTIVE
Kevin Lee

COMPENSATION 2026

Salary$862,339
Stock Awards$1,724,800
Incentive Plan Pay$543,642
All Other Comp.$249,395
Total$6,341,473

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 23, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
288

PRICE TARGET

Target High$12.00
Target Low$8.00
Target Median$12.00
Target Consensus$10.67

UPCOMING EARNINGS

DateOct 29, 2026
DayThursday
Rev. Est.$12.22M
OCT
29
THU

PRICE

$4.29 ▲ UP 1.30% (+$0.06)
$4.20$4.24$4.289:30 AM10:08 AM10:45 AM11:23 AM12:01 PM12:38 PM1:16 PM4.29

About Bicycle Therapeutics plc

https://www.bicycletherapeutics.com ↗

Bicycle Therapeutics plc is a UK-based clinical-stage biopharma developing novel Bicycle-based medicines for underserved diseases, with lead oncology candidates in Phase I/II trials and collaborations across oncology, ophthalmology, and other ther...

INDUSTRY

Biotechnology

A PRODUCT BICYCLE THERAPEUTICS PLC IS KNOWN FOR

Zelenectide pevedotin (BT8009)
Zelenectide pevedotin (BT8009)

Zelenectide pevedotin is a Bicycle Toxin Conjugate in Phase 2/3 trials targeting Nectin-4–positive advanced solid tumors, representing Bicycle Therapeutics' leading innovative cancer therapy candidate.

COMPETITORS

COMPETITOR
ABBV COMPARE
AZN COMPARE
CRBP COMPARE
GILD COMPARE
PFE COMPARE

Revenue by Products

IconPRODUCTQ1-2021Q3-2021
Target 6 Material Right— $1.1M
Target Four Material Right$300K —

ETFS HOLDING THIS STOCK

ETFS HOLDING
15
LISTED HERE
8
RANKED BY POSITION SIZE
IBB
0.01% · 277.0K
BBC
0.65% · 77.4K
SBIO
0.12% · 67.6K
GWX
0.01% · 31.3K
QQQS
0.45% · 23.8K
APIE
0.01% · 20.3K
MEDX
0.28% · 11.4K
BIB
0.01% · 1.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
49.54%
HOLDERS
139
TOP 12 OF 139 · RANKED BY POSITION SIZE
Baker Bros. Advisors LP
10.9M sh · $50.51M
Fcpm Iii Services B.V.
3.5M sh · $16.09M
Armistice Capital, LLC
3.4M sh · $15.77M
Long Focus Capital Management, LLC
3.3M sh · $15.36M
Westfield Capital Management Co LP
3.0M sh · $21.35M
Siren, L.L.C.
2.0M sh · $15.58M
Acadian Asset Management LLC
2.0M sh · $9.11M
Gsk Plc
1.5M sh · $7.1M
Price T Rowe Associates Inc /Md/
1.4M sh · $10.72M
Principal Financial Group Inc
1.2M sh · $5.45M
Candriam S.C.A.
1.2M sh · $9.07M
Millennium Management LLC
1.1M sh · $8.16M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book5
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF SCIENTIFIC OFFICER
Skynner Michael
Purchase · 60.0K shares
2026-07-15
★
OFFICER: CHIEF FINANCIAL OFFICER
Thompson Travis Alvin
Purchase · 60.0K shares
2026-07-15
★
OFFICER: CHIEF OPERATING OFFICER
Perry Jennifer Scott
Purchase · 60.0K shares
2026-07-15
★
OFFICER: CHIEF PROD & SUPPLY CHAIN OFF
Hannay Michael Charles Ferguson
Purchase · 60.0K shares
2026-07-15

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
EQUAL WEIGHT 1
OUTPERFORM 1
SECTOR PERFORM 1
MARKET OUTPERFORM 1
5 GRADES IN THE LAST 12 MONTHS
Needham BUY Morgan Stanley EQUAL WEIGHT Oppenheimer OUTPERFORM RBC Capital SECTOR PERFORM Citizens MARKET OUTPERFORM

SECTORS PEERS

PEERPRICE
OMER$19.00COMPARE
LXRX$2.25COMPARE
FDMT$14.47COMPARE
PRTA$9.67COMPARE
CMPX$2.37COMPARE
FULC$3.83COMPARE
NMRA$1.35COMPARE
ADCT$1.31COMPARE